API-I-007

API-I-007 is a discovery-stage therapeutic candidate being developed by Aprilbio for the treatment of Inflammatory Bowel Disease (IBD). The drug is part of Aprilbio's pipeline, which leverages their proprietary SAFA (Serum Albumin Fragment Associated) technology. The SAFA platform is designed to extend the half-life of therapeutic proteins by utilizing a human anti-serum albumin antibody fragment, potentially allowing for improved dosing schedules and sustained efficacy in chronic inflammatory conditions. While the specific molecular target and modality of API-I-007 have not been publicly disclosed, it represents a key early-stage asset in the company's immunology portfolio.